Centessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Recommendation of “Buy” by Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $25.83.

CNTA has been the topic of a number of research reports. B. Riley began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 target price on the stock. Jefferies Financial Group increased their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Finally, Guggenheim increased their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th.

Centessa Pharmaceuticals Stock Down 2.8 %

Shares of CNTA stock opened at $17.01 on Friday. Centessa Pharmaceuticals has a 1 year low of $6.65 and a 1 year high of $18.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The business’s fifty day moving average is $16.87 and its 200-day moving average is $14.11. The stock has a market cap of $2.24 billion, a PE ratio of -11.12 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the sale, the insider now directly owns 183,266 shares of the company’s stock, valued at $3,122,852.64. This represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Tia L. Bush sold 17,813 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total transaction of $320,634.00. Following the sale, the chief technology officer now owns 147,615 shares of the company’s stock, valued at approximately $2,657,070. This represents a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 368,023 shares of company stock worth $6,335,574 over the last quarter. Corporate insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of CNTA. Mirae Asset Global Investments Co. Ltd. increased its position in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares during the last quarter. Atria Investments Inc raised its position in Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after acquiring an additional 1,116 shares in the last quarter. Quarry LP raised its position in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Centessa Pharmaceuticals by 99.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after acquiring an additional 6,785 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.